製品名:O-[2-[(2-methylpropan-2-yl)oxy]ethyl]hydroxylamine

IUPAC Name:O-[2-(tert-butoxy)ethyl]hydroxylamine

CAS番号:1023742-13-3
分子式:C6H15NO2
純度:95%+
カタログ番号:CM325604
分子量:133.19

包装単位 有効在庫 価格(USD) 数量
CM325604-100g in stock ƏƏǕ
CM325604-500g in stock șňŭƏ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1023742-13-3
分子式:C6H15NO2
融点:-
SMILESコード:NOCCOC(C)(C)C
密度:
カタログ番号:CM325604
分子量:133.19
沸点:
MDL番号:
保管方法:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Encorafenib plus Binimetinib
U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.